ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 1464

Lupus Flares More Common in Patients on Dialysis Compared to After Renal Transplant: A Systematic Review and Meta-analysis
Abstract Number: 1465

Blood-dominant Disease in Older-onset Lupus: A Systematic Review and Meta-analysis
Abstract Number: 1466

Impact of Co-morbid Depression on Systemic Lupus Erythematosus Hospitalizations: Insights from National Readmission Database 2020
Abstract Number: 1467

Antiphospholipid Antibodies and the Risk of Diffuse Alveolar Hemorrhage in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Abstract Number: 1468

Prediction of Cardiovascular Disease in Patients with Systemic Lupus Erythematosus Using a Machine Learning Algorithm for Time-to-Event Outcomes: Random Survival Forest
Abstract Number: 1469

Prevalence of Cardiovascular Disease in a Populations Based Registry of Patients with Systemic Lupus Erythematosus
Abstract Number: 1470

SARS-CoV-2 Antibody Formation After COVID-19 Vaccination in SLE Patients Treated with Belimumab: Single-Center Prospective Observational Study
Abstract Number: 1471

A Comparative Study of Lupus Nephritis Class II and IgA Nephropathy: Renal Disease Other Than Lupus Nephritis in Systemic Lupus Erythematosus Patients
Abstract Number: 1472

Prevalence of Hepatic Injury in Patients with Systemic Lupus Erythematosus: A 28-Year Single Center Experience
Abstract Number: 1473

Mortality from Diseases of the Nervous System in Patients with Lupus in the past Two Decades
Abstract Number: 1474

Associations and Outcomes of Critical Peripheral Ischemia in Systemic Lupus Erythematosus (SLE): Data from Indian SLE Inception Cohort for Research (INSPIRE)
Abstract Number: 1475

Retrospective Study of Obesity on Clinical and Immunological Features in Systemic Lupus Erythematosus Using AI Software Deep 6 and EPIC Slicer Dicer
Abstract Number: 1476

Discriminating Disease Flare from Infection in Febrile Patients with Systemic Lupus Erythematosus Admitted to a Safety-Net Hospital System: A Retrospective, Multicenter Study
Abstract Number: 1477

Clinical and Economic Burden of Herpes Zoster in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Abstract Number: 1478

Presentation and Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort and a Systematic Literature Review

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].